GNFT

GENFIT S.A.

3.66 USD
+0.01 (+0.27%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

GENFIT S.A. stock is down -4.44% since 30 days ago. The next earnings date is Apr 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 February’s closed higher than January.

About GENFIT S.A.

Genfit S.A. discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. Elafibranor is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test.